[Well-controlled comparative study on @entity5646 and XXXX in the treatment of complicated @entity293 ].

@entity1 @entity16397 @entity72429 @entity5647 @entity325 @entity293 @entity2891 @entity57735 @entity5646 @entity5579
A well-controlled comparative study was conducted in order to evaluate the efficacy, safety and usefulness of the @entity16397 antibiotic @entity5646 ( @entity5647 ) in complicated @entity293 ( @entity293 ) using @entity2891 ( @entity5579 ) as the control drug. @entity1 with complicated @entity293 due to Gram-negative bacteria were examined. However, in @entity325 , the cases caused by Gram-negative and Gram-positive bacteria were also examined. Both drugs were administered 1 g, twice a day by intravenous drip infusion for 5 days. Overall clinical efficacy was evaluated by the criteria proposed by the @entity293 committee in Japan. Of the total 394 cases, the clinical efficacy was evaluated for 152 cases in the @entity5647 group and 143 cases in the @entity5579 group excluding 99 cases of exclusion or dropout. There was no statistically significant difference in the back ground characteristics between the 2 groups. The overall clinical efficacy rate was 55.3% for @entity5647 and 55.2% for @entity5579 with difference not significant. As for clinical efficacy, in the monomicrobial infection after postprostatectomy ( @entity57735 ), @entity5647 was superior to @entity5579 (P less than 0.05), whereas in the @entity325 without indwelling catheter ( @entity72429 ), @entity5579 was superior to @entity5647 (P less than 0.1). The overall bacteriological eradication rate was 77.2% for @entity5647 and 74.5% for @entity5579 . For Gram-negative bacteria only the eradication rate for @entity5647 (83.2%) was superior to that for @entity5579 (74.6%). This was probably due to the stability of @entity5647 to beta-lactamase. Side effects were observed in 3 cases out of 201 in the @entity5647 group and 5 cases out of 189 in the @entity5579 group. No severe abnormal laboratory finding was observed in any group; there was no significant difference between the 2 groups. Consequently, @entity5647 was judged to be an antibiotic with clinical usefulness equal to, or even superior to that of @entity5579 .
